Gene Therapy for Primary Immunodeficiency

• Main Authors: Benjamin C. Houghton, Claire Booth
• Format: Article
• Language: English
• Published: Wolters Kluwer 2021-01-01
• Series: HemaSphere
• Online Access: http://journals.lww.com/10.1097/HS9.0000000000000509

Over the past 3 decades, there has been significant progress in refining gene therapy technologies and procedures. Transduction of hematopoietic stem cells ex vivo using lentiviral vectors can now create a highly effective therapeutic product, capable of reconstituting many different immune system dysfunctions when reinfused into patients. Here, we review the key developments in the gene therapy landscape for primary immune deficiency, from an experimental therapy where clinical efficacy was marred by adverse events, to a commercialized product with enhanced safety and efficacy. We also discuss progress being made in preclinical studies for challenging disease targets and emerging gene editing technologies that are showing promising results, particularly for conditions where gene regulation is important for efficacy.